

From Serendipity to Rational Design; Taking Molecular Glue Degraders to New Heights

Bernhard Fasching

Monte Rosa Therapeutics, Klybeckstrasse 191, 4057 Basel Switzerland
bfasching@monterosatx.com

Targeted Protein Degradation has been identified in recent years as an attractive, novel way to deeply modulate protein pathways, employing the body's natural mechanisms to selectively eliminate therapeutically relevant proteins. Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines, using its proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates). The platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection, and computational chemistry. This has resulted in a growing pipeline of drug discovery programs that are progressing towards the clinic. This talk will cover history of MGDs and introduction to Monte Rosa Therapeutics.

monterosatx.com